trending Market Intelligence /marketintelligence/en/news-insights/trending/2NaDqjDqSrtGxIo9cA5soA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Blackstone funds to buy Japan's AYUMI Pharmaceutical

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks

Gauging Supply Chain Risk In Volatile Times


Blackstone funds to buy Japan's AYUMI Pharmaceutical

Private equity funds managed by Blackstone Group LP agreed to purchase Japanese pharmaceutical company AYUMI Pharmaceutical Corp., marking the firm's first control private equity investment in the country.

The agreement was reached with local private equity firm Unison Capital Inc. and medical information site company M3 Inc.

Terms of the deal, expected to close in the second quarter, were not disclosed.

Bloomberg News earlier reported that Unison was evaluating a potential sale of the anti-rheumatic drug maker for up to US$1 billion.